<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1921">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015478</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 21-0378-01</org_study_id>
    <nct_id>NCT05015478</nct_id>
  </id_info>
  <brief_title>Rhythmic Light Therapy for Alzheimer's Disease Patients</brief_title>
  <official_title>Phase 1 - The Use of Rhythmic Light Therapy to Entrain Gamma Oscillations and the Circadian System in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator will investigate how light delivering 40 hertz (Hz) affects subjective sleep&#xD;
      and cognition in a controlled laboratory study. A lab study will allow the collection of&#xD;
      electroencephalogram (EEG) data, perform cognitive tests, and observe the response in those&#xD;
      with mild cognitive impairment (MCI) compared to a healthy control group (HC).&#xD;
&#xD;
      Participants will attend two study sessions over the course of two weeks. During both&#xD;
      sessions, all participants will experience 10 minutes of a low-level light, followed by a&#xD;
      data collection period which involves a sleepiness rating, an electroencephalogram (EEG)&#xD;
      recording, and a computerized memory test. Participants will then experience either a RL or a&#xD;
      placebo RL condition for one hour, after which there will be a second data collection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator will demonstrate the effect of 40 hertz (Hz) rhythmic light (RL) to promote&#xD;
      gamma wave entrainment (rhythmic light [RL]) on: brain response (electroencephalography&#xD;
      [EEG]); cognitive performance (working memory task); and subjective sleepiness&#xD;
      (questionnaires). The study will recruit 20 adult mild cognitive impairment (MCI) patients&#xD;
      and 20 healthy, age-matched controls (HC) to participate in this study.&#xD;
&#xD;
      Sessions will initiate with a 10-minute adaptation period to a low-level ambient light&#xD;
      providing illuminance of 15 lux at participants' eye level on a vertical plane, followed by a&#xD;
      pre-exposure data collection period, including Karolinska Sleepiness Scale (KSS), EEG, and a&#xD;
      working memory task. Participants will experience either 40 Hz RL or placebo RL conditions&#xD;
      for a duration of 1 hour, followed by the second data collection period. On the second data&#xD;
      collection day, participants will experience the other condition, so that all participants&#xD;
      experience both lighting conditions. The experimental sessions will start at 14:00 on each&#xD;
      experimental day which will be separated by 1 week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2022</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Electroencephalography (EEG) power at 40 hertz (Hz)</measure>
    <time_frame>baseline</time_frame>
    <description>Electroencephalography (EEG) recordings, lasting 3-minutes each, will occur 2 times per experimental session. The power at 40 hertz (Hz), 4-8 Hz (theta), and 30-55 Hz (low gamma) frequency ranges will be calculated at each electrode site. Entrainment to the 40 Hz rhythmic stimulation will be assessed in terms of increases in power at 40 Hz.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electroencephalography (EEG) power at 40 hertz (Hz)</measure>
    <time_frame>1 hour after intervention</time_frame>
    <description>Electroencephalography (EEG) recordings, lasting 3-minutes each, will occur 2 times per experimental session. The power at 40 hertz (Hz), 4-8 Hz (theta), and 30-55 Hz (low gamma) frequency ranges will be calculated at each electrode site. Entrainment to the 40 Hz rhythmic stimulation will be assessed in terms of increases in power at 40 Hz.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Sleepiness using the Karolinska Sleepiness Scale (KSS)</measure>
    <time_frame>baseline</time_frame>
    <description>The Karolinska Sleepiness Scale (KSS) outcome prompts participants to rate how sleepy or alert they are feeling on a scale ranging from 1 to 9, where 1 = &quot;very alert,&quot; 3 = &quot;rather alert,&quot; 5 = &quot;neither alert nor sleepy,&quot; 7 = &quot;sleepy, but no difficulty remaining awake,&quot; and 9 = &quot;very sleepy, fighting sleep, an effort to remain awake.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Sleepiness using the Karolinska Sleepiness Scale (KSS)</measure>
    <time_frame>1 hour after intervention</time_frame>
    <description>The Karolinska Sleepiness Scale (KSS) outcome prompts participants to rate how sleepy or alert they are feeling on a scale ranging from 1 to 9, where 1 = &quot;very alert,&quot; 3 = &quot;rather alert,&quot; 5 = &quot;neither alert nor sleepy,&quot; 7 = &quot;sleepy, but no difficulty remaining awake,&quot; and 9 = &quot;very sleepy, fighting sleep, an effort to remain awake.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition using a working memory task</measure>
    <time_frame>baseline</time_frame>
    <description>Participants view a serial visual display of letters and math problems. They are asked to hold the letters in memory while simultaneously determining if the simple math problems are correct (e.g., 7+5=13). Performance is assessed in percent correct and by measuring accuracy and Reaction Time (RT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition using a working memory task</measure>
    <time_frame>1 hour after intervention</time_frame>
    <description>Participants view a serial visual display of letters and math problems. They are asked to hold the letters in memory while simultaneously determining if the simple math problems are correct (e.g., 7+5=13). Performance is assessed in percent correct and by measuring accuracy and Reaction Time (RT).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Active Tailored Rhythmic Lighting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 hour intervention period where active lighting is experienced by participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive Placebo Rhythmic Lighting</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 hour intervention period where an inactive, placebo lighting condition is experienced by participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tailored Rhythmic Lighting Intervention</intervention_name>
    <description>40 hertz (Hz) rhythmic lighting (RL) for a duration of 1 hour. The flicker frequency of the 40 Hz RL will be 40 Hz and the stimulation will be a square wave with a 50 % duty cycle (i.e., 12.5 milliseconds light- on and 12.5 milliseconds light-off). The RL will provide a 30 lux of red light on a vertical plane at the eye level.</description>
    <arm_group_label>Active Tailored Rhythmic Lighting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Rhythmic Lighting Intervention</intervention_name>
    <description>Placebo rhythmic light (RL) for a duration of 1 hour. In the placebo RL condition, the duty cycle will be delivered with a random interval determined by a Poisson process with an average interval of 40 hertz (Hz). The placebo RL conditions will provide a 30 lux of red light on a vertical plane at the eye level.</description>
    <arm_group_label>Inactive Placebo Rhythmic Lighting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be diagnosed with amnestic mild cognitive impairment or mild&#xD;
             Alzheimer's disease, as defined by a Montreal Cognitive Assessment (MoCA) score&#xD;
             between 17 and 25&#xD;
&#xD;
          -  For the age-matched healthy controls, participants must not be diagnosed with mild&#xD;
             cognitive impairment or Alzheimer's disease related dementias (MoCA score above 25).&#xD;
&#xD;
          -  Participants must score a 5 or less in the Pittsburgh Sleep Quality Index (PSQI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All participants must not be taking sleeping medication or oral melatonin&#xD;
&#xD;
          -  Presence of another brain disease that fully explains the dementia (extensive brain&#xD;
             vascular disease, Parkinson's disease, dementia with Lewy bodies, traumatic brain&#xD;
             injury, or multiple sclerosis)&#xD;
&#xD;
          -  residence in a skilled nursing facility or long-term care&#xD;
&#xD;
          -  Major organ failure (e.g., kidney failure)&#xD;
&#xD;
          -  Uncontrolled generalized disorders such as hypertension or diabetes&#xD;
&#xD;
          -  Obstructing cataracts, macular degeneration, and blindness&#xD;
&#xD;
          -  Severe sleep apnea or restless leg syndrome&#xD;
&#xD;
          -  History of epilepsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariana Figueiro, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Plitnick, BSN</last_name>
    <phone>518-248-4131</phone>
    <email>barbara.plitnick@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariana Figueiro, PhD</last_name>
    <phone>518-366-9306</phone>
    <email>mariana.figueiro@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Light and Health Research Center</name>
      <address>
        <city>Menands</city>
        <state>New York</state>
        <zip>12204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990 May;52(1-2):29-37.</citation>
    <PMID>2265922</PMID>
  </reference>
  <reference>
    <citation>Nasreddine ZS, Phillips NA, BÃ©dirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. Erratum in: J Am Geriatr Soc. 2019 Sep;67(9):1991.</citation>
    <PMID>15817019</PMID>
  </reference>
  <reference>
    <citation>Buysse DJ, Reynolds CF 3rd, Monk TH, Hoch CC, Yeager AL, Kupfer DJ. Quantification of subjective sleep quality in healthy elderly men and women using the Pittsburgh Sleep Quality Index (PSQI). Sleep. 1991 Aug;14(4):331-8. Erratum in: Sleep 1992 Feb;15(1):83.</citation>
    <PMID>1947597</PMID>
  </reference>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>July 13, 2022</last_update_submitted>
  <last_update_submitted_qc>July 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Mariana Figueiro</investigator_full_name>
    <investigator_title>Professor, Population Health Science and Policy</investigator_title>
  </responsible_party>
  <keyword>Light Treatment</keyword>
  <keyword>Circadian Rhythms</keyword>
  <keyword>Gamma Wave Entrainment</keyword>
  <keyword>Rhythmic Light</keyword>
  <keyword>Mild Alzheimer's Disease</keyword>
  <keyword>Sleep</keyword>
  <keyword>Memory</keyword>
  <keyword>Electroencephalogram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

